Clinical trial · Interventional
Role of CEUS as a Secondary Diagnostic Modality
Role of Sonazoid-enhanced Ultrasound as a Secondary Diagnostic Modality in Non-invasive Diagnostic Algorithms for Hepatocellular Carcinoma
NCT04494022CI-TRIAL-00046322unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To determine the role of contrast-enhanced ultrasound (CEUS) as a second-line imaging modality after gadoxetate-enhanced MRI (Gd-EOB-MRI) for identifying hepatocellular carcinoma (HCC) among at-risks observations.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| contrast enhanced ultrasound | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Cross-sectional image only
- description
- Image set which consists of a Cross-sectional image only.
- type
- ACTIVE_COMPARATOR
- label
- Cross-sectional image with CEUS
- description
- The same participants with Arm1. But image set will consist of a Cross-sectional image and CEUS.
- interventionNames
- Diagnostic Test: contrast enhanced ultrasound
Primary outcomes (2)
- measure
- Compared the image features of CEUS and Gd-EOB-MRI in at-risk observation
- timeFrame
- 1. For 3 days after undergoing CEUS to check the complication of CEUS, per each participants. 2. The time interval between CEUS and Gd-EOB-MRI should not be exceed 4 weeks.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * at risk of HCC by Liver Imaging Reporting and Data System (LI-RADS) * at least one treatment-naïve solid hepatic observation (≥1 cm) while surveillance using US, CT or MRI * signed informed consent Exclusion Criteria: * congestive hepatopathies * severe cardiovascular dysfunction * no recent cross-sectional images within 4 weeks * suboptimal cross-sectional images quality
References
Publications (0)
Data not yet available
No reference posted for this study.